Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358863 · ClinicalTrials.gov registry record · NA
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
A NA study, sponsored by Georgetown University.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT02358863: Clinical Trial NA study, sponsored by Georgetown University.
NCT02358863 is a NA study that was terminated before completion, run by Georgetown University. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02358863, a NA study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tumor; based on the results of these tests, a patient will be assigned to a chemotherapy treatment.
Primary Outcome
Objective response rate is the sum of partial responses plus complete responses and will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions.
Interventions
- DRUG Modified FOLFOX6
- DRUG Docetaxel/Capecitabine
- DRUG Cisplatin/Irinotecan
- DRUG Cisplatin/Docetaxel
- DRUG IRI/EPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-11 |
| Phase | NA |
Why NCT02358863 stopped before completion
NCT02358863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Modified FOLFOX6 is the first listed.
NCT02358863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02358863 about?
NCT02358863 is a clinical study titled "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach". The purpose of this study is to determine whether molecular profile-directed therapy (otherwise known as personalized treatment) can improve the effectiveness of standard chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests will be performed on a sample of tu...
What is the current status of trial NCT02358863?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2015-02. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02358863?
The interventions under investigation include: Modified FOLFOX6 (DRUG), Docetaxel/Capecitabine (DRUG), Cisplatin/Irinotecan (DRUG), Cisplatin/Docetaxel (DRUG), IRI/EPI (DRUG).
Who is sponsoring clinical trial NCT02358863?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02358863's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia